Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000179 · ClinicalTrials.gov registry record · Phase 3
Agitation in Alzheimer's Disease
A Phase 3 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 3
- Development phase
NCT00000179: Completed Phase 3 study, sponsored by National Institute on Aging (NIA).
NCT00000179 is a Phase 3 study that has completed, run by National Institute on Aging (NIA). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000179, a Phase 3 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs for agitation in AD patients. Behavior management, a non drug approach, has been effective in reducing signs of agitation. Researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in AD patients and determine which is the best treatment. The Alzheimer's Disease Cooperative Study, with funding from the National Institute on Aging, is conducting an agitation treatment program at 21 sites in 16 States. This study will assess which of the above treatments is most effective.
Interventions
- DRUG Trazodone
- DRUG Haloperidol
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
What the finished NCT00000179 record still lists
NCT00000179 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which Trazodone is the first listed.
NCT00000179 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000179 about?
NCT00000179 is a clinical study titled "Agitation in Alzheimer's Disease". Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs ...
What is the current status of trial NCT00000179?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00000179?
The interventions under investigation include: Trazodone (DRUG), Haloperidol (DRUG).
Who is sponsoring clinical trial NCT00000179?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.